Current:Home > MyHow randomized trials and the town of Busia, Kenya changed economics -Elevate Profit Vision
How randomized trials and the town of Busia, Kenya changed economics
TradeEdge Exchange View
Date:2025-04-09 09:05:38
In the early 90s, when a young economist named Michael Kremer finished his PhD, there had been a few economic studies based on randomized trials. But they were rare. In part because randomized trials – in which you recruit two statistically identical groups, choose one of them to get a treatment, and then compare what happens to each group – are expensive, and they take a lot of time.
But then, by chance, Michael had the opportunity to run a randomized trial in Busia, Kenya. He helped a nonprofit test whether the aid they were giving to local schools helped the students. That study paved the way for more randomized trials, and for other economists to use the method.
On today's show, how Busia, Kenya, became the place where economists pioneered a more scientific way to study huge problems, from contaminated water to low graduation rates, to HIV transmission. And how that research changed government programs and aid efforts around the world.
This episode was produced by James Sneed with help from Willa Rubin. It was engineered by James Willetts. It was fact-checked by Sierra Juarez and Emma Peaslee. It was edited by Molly Messick. Jess Jiang is our acting executive producer.
Help support Planet Money and get bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.
Always free at these links: Apple Podcasts, Spotify, Google Podcasts, NPR One or anywhere you get podcasts.
Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.
Music: "Smoke and Mirrors," "Slowmotio," and "Icy Boy."
veryGood! (39)
Related
- Trump suggestion that Egypt, Jordan absorb Palestinians from Gaza draws rejections, confusion
- Corporate Giants Commit to Emissions Targets Based on Science
- Another $1.2 Billion Substation? No Thanks, Says Utility, We’ll Find a Better Way
- India's population passes 1.4 billion — and that's not a bad thing
- Civic engagement nonprofits say democracy needs support in between big elections. Do funders agree?
- Rust armorer facing an additional evidence tampering count in fatal on-set shooting
- Caught Off Guard: The Southeast Struggles with Climate Change
- Sharon Stone Serves Up Sliver of Summer in Fierce Bikini Photo
- Intel's stock did something it hasn't done since 2022
- How a secret Delaware garden suddenly reemerged during the pandemic
Ranking
- 'No Good Deed': Who's the killer in the Netflix comedy? And will there be a Season 2?
- Afghan evacuee child with terminal illness dies while in federal U.S. custody
- Medical students aren't showing up to class. What does that mean for future docs?
- Could the Flight Shaming Movement Take Off in the U.S.? JetBlue Thinks So.
- 'Survivor' 47 finale, part one recap: 2 players were sent home. Who's left in the game?
- South Carolina Has No Overall Plan to Fight Climate Change
- South Carolina Has No Overall Plan to Fight Climate Change
- In Latest Blow to Solar Users, Nevada Sticks With Rate Hikes
Recommendation
Dick Vitale announces he is cancer free: 'Santa Claus came early'
Biden hosts India's Modi for state visit, navigating critical relationship amid human rights concerns
Afghan evacuee child with terminal illness dies while in federal U.S. custody
Debt limit deal claws back unspent COVID relief money
McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales
The drug fueling another wave of overdose deaths
Get 2 Peter Thomas Roth Anti-Aging Cleansing Gels for Less Than the Price of 1
Coastal biomedical labs are bleeding more horseshoe crabs with little accountability